ADIL - Adial Pharmaceuticals Inc
NYSE * Health Care * Biotechnology
$0.22
$-0.01 (-4.00%)
About Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.
ADIL Key Statistics
Market Cap
$6.01M
P/B Ratio
1.33
EPS
$-0.60
Employees
7
How ADIL Compares to Peers
P/E Rank
N/A
of 5
Margin Rank
N/A
of 5
Growth Rank
N/A
of 5
Size Rank
#6
of 6
Adial Pharmaceuticals Inc Company Information
- Headquarters
- Virginia; U.S.A
- Website
- www.adialpharma.com
- Sector
- Health Care
- Industry
- Biotechnology